TARGANTA THERAPEUTICS CORP has a total of 21 patent applications. Its first patent ever was published in 2007. It filed its patents most often in Australia, Canada and China. Its main competitors in its focus markets pharmaceuticals, basic materials chemistry and organic fine chemistry are HIBERNATION THERAPEUTICS A KF LLC, SYMBOLLON CORP and HIBERNATION THERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | Canada | 3 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Brazil | 2 | |
#7 | EAPO (Eurasian Patent Organization) | 2 | |
#8 | Mexico | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Basic materials chemistry | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Preservation of human bodies | |
#4 | Special acyclic compounds | |
#5 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Moeck Gregory | 12 |
#2 | Lehoux Dario | 11 |
#3 | Parr Thomas R | 9 |
#4 | Beaulieu Sylvain | 4 |
#5 | Dario Lehoux | 4 |
#6 | Mckay Geoffrey | 4 |
#7 | Etienne Pierre | 4 |
#8 | Rafai Far Adel | 3 |
#9 | Baines Simon | 3 |
#10 | Wilcox Mark Harvey | 3 |
Publication | Filing date | Title |
---|---|---|
EP2424559A1 | Methods of treating bacterial infections using oritavancin | |
EA020490B1 | Method of treatment of bacterial infection | |
EP2324041A2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | |
EP2278989A2 | Methods of inhibiting and treating biofilms using glycopeptide antibiotics | |
EA017564B1 | Method of inhibiting clostridium difficile by administration of oritavancin | |
WO2008118784A1 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | |
AU2007346657A1 | Use of oritavancin for prevention and treatment of anthrax |